Jiangsu Hengrui's Second Indication Application for Camrelizumab to be Approved for Marketing in China

According to NMPA, the second indication of Jiangsu Hengrui's PD-1Camrelizumab to treat liver cancer is close to be approved for martketing soon. Camrelizumab is the 3rd PD-1 approved in China and is going to be the first PD-1 in the treat of hepatocellular carcinoma (HCC) in China.

With more PD-(L)1s in the treatment of liver cancer to be marketed in China, such as Camrelizumab and the second indication of Roche's Tecentriq, China will have more innovative second-line and first-line therapies for the disease, marking Chinese hepatocellular carcinoma enters the era of tumor immunity.

Recently a multi-centered, open-ended, parallel, randomized, phase II clinical trials of Hengrui's Carizolizumab in patients with advanced stage hepatocellular carcinoma (HCC) led by Chinese researchers were published in The Lancet Oncology, a top international journal, with an impact factor (SCI) of 35.386.

Primary hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. It has the highest mortality rate in the world, accounting for 9.1% of global cancer mortality. According to the liver cancer epidemiological data released in 2016, China is the country with the highest incidence of hepatocellular carcinoma, accounting for 55% of the global total.

Related Reading: 

Hengrui's Class 1 New Drug Fluzoparib has been Applied for New Clinical Trials

Register as Visitor to CPhI China 2020!